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Background
Nucleophosmin (NPM1) gene and fms-like tyrosine kinase 3 gene-internal tandem dupli-
cation (FLT3-ITD) mutations are the most frequent mutations in patients with cytogeneti-
cally normal (CN)-AML. We analyzed the prognostic impact of these mutations and their 
interactions in adults with CN-AML. 
Methods
NPM1 mutation (NPM1mut) and FLT3-ITD mutation (FLT3-ITD+) were analyzed by 
GeneScan and PCR assays of bone marrow samples obtained from 121 adult patients with 
CN-AML (age≤60 years at diagnosis). 
Results
The incidence of FLT3-ITD+ was higher in the NPM1mut group than in the wild-type NPM1 
gene (NPM1wt) group. The patients were divided according to their mutation status into 
the NPM1mut/FLT3-ITD (isolated NPM1mut), NPM1mut/FLT3-ITD+ or NPM1wt/FLT3-ITD-,
and NPM1wt/FLT3-ITD+ (isolated FLT3-ITD+) groups. The isolated NPM1mut group 
showed significantly better clinical outcomes in terms of relapse rate, 5-year relapse-free 
survival (RFS), and overall survival (OS) than the other groups. In contrast, the isolated 
FLT3-ITD+ group had a higher relapse rate and shorter RFS and OS than the other groups. 
The 5-year RFS rate was much higher among the patients who underwent allogeneic stem 
cell transplantation (alloSCT) than among those treated with high-dose cytarabine che-
motherapy (HDAC) only as consolidation therapy in the isolated NPM1mut group and 
the NPM1mut/FLT3-ITD+ or NPM1wt/FLT3-ITD- group.
Conclusion
Adult patients with CN-AML carrying isolated NPM1mut and isolated FLT3-ITD+ exhibit 
different clinical outcomes than those with NPM1mut/FLT3-ITD+ or NPM1wt/FLT3-ITD-. 
Although isolated NPM1mut leads to favorable clinical outcomes of CN-AML, the role 
of alloSCT in such patients remains to be considered.
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INTRODUCTION
  AML is a clinically and genetically heterogeneous disease. 
Three cytogenetically defined risk groups (favorable, inter-
mediate, and adverse) are used to design risk-adapted treat-
ment protocols for patients with AML. However, about 
35-50% of the successfully karyotyped patients lack clonal 
chromosomal aberrations [1], and the prognostic implications 
have not been clearly established for cytogenetically normal 
(CN)-AML [2]. Therefore, it is important to develop a molec-Korean J Hematol 2010;45:36-45.
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ular-level genetic approach for discriminating between prog-
nostically different subsets of CN-AML. 
  In the recent years, CN-AML has been identified as a 
heterogeneous disease with mutations of the nucleophosmin 
(NPM1) and fms-like tyrosine kinase 3 (FLT3) genes. NPM1, 
encoded by the NPM1 gene on chromosome 5q35, is a multi-
functional nucleocytoplasmic shuttling protein localized pri-
marily in the nucleolus but shuttles rapidly between the 
nucleus and the cytoplasm. The protein appears to be im-
portant for various cellular processes. NPM may assist in 
ribosomal protein assembly [3] and maintain genomic stabil-
ity through its participation in DNA repair [4]. It also plays 
a crucial role in cell cycle regulation and apoptosis via its 
interactions with tumor suppressor p53 and alternate reading 
frame protein [5, 6].
  The NPM1 gene frequently acts as a target of chromosomal 
translocations and causes the cytoplasmic dislocation of pro-
teins in various types of leukemia and lymphoma, indicating 
its role in malignant transformation. Recent studies have 
demonstrated that aberrant cytoplasmic localization of NPM 
(NPMc+) in leukemic blasts is associated with mutations 
at exon-12 of the NPM1 gene [7-9]. NPM1 exon-12 mutations 
can encode mutant proteins with a novel nuclear export 
signal (NES) motif inserted at the C-terminus and disruption 
of the nucleolar localization signal due to mutations of trypto-
phan residues 288 and 290 [7, 8]. Such mutations are classified 
according to the type of NES motif inserted into the mutant 
protein. In adult NPMc+ AML, mutation ‘A’ (tandem duplica-
tion of TCTG) accounts for approximately 80% of all the 
NPMc+ cases [9]. Mutations at NPM1 exon-12 and the re-
sultant shift of NPM1 into the cytoplasm are found in approx-
imately 35% of the adults with AML. One of the most fre-
quent mutations seen in CN-AML is NPM1 mutation 
(NPM1mut), found in 45.7-64% of the patients. Besides the 
characteristic biological features such as increased frequency 
of monocytic leukemia and distinctive gene expression pro-
files, patients with CN-AML carrying isolated NPM1mut 
show better clinical outcomes in terms of the responsiveness 
to chemotherapy or disease-free survival (DFS) than those 
with the wild-type NPM1 ( NPM1wt) gene [9-12].
  FLT3 belongs to the class III receptor tyrosine kinase 
family. It is expressed in early hematopoietic progenitors 
and its dimerization by the FLT3 ligand induces growth 
control signals in normal hematopoiesis. The FLT3 gene maps 
to chromosome band 13q12 [13], and an internal tandem 
duplication (ITD) of the gene (FLT3-ITD) has been detected 
in 20-30% of the young adults with AML [14]. The duplica-
tion involves a segment of the juxtamembrane domain-cod-
ing sequence, which frequently involves exon-14 and rarely 
intron-14 or exon-15, and is always in-frame [14]. In support 
of the potential role of this mutation in leukemogenesis, 
FLT3-ITD from patients with AML has been shown to induce 
autonomous proliferation in cytokine-dependent cell lines. 
In contrast to NPM1mut, patients with isolated FLT3-ITD 
mutation (FLT3-ITD+) show poor clinical outcomes, similar 
to those with poor-risk cytogenetics [9, 12, 14].
  Several studies have attempted to identify the interactions 
between these frequent mutations and their prognostic im-
plications for patients with CN-AML. On the basis of these 
reports, the recently updated National Comprehensive 
Cancer Network (NCCN) Guidelines [15] recommend that 
isolated NPM1mut and FLT3-ITD+ CN-AML should be re-
garded as better-risk and poor-risk cytogenetics, respectively; 
hence, transplantation as a postremission therapy should be 
reserved until relapse in patients with CN-AML carrying 
isolated NPM1mut. In contrast, patients with FLT3-ITD+ 
CN-AML should be enrolled in clinical trials as the standard 
therapy on account of their poor prognosis. Nonetheless, 
controversy exists as to the prognostic significance of these 
two mutations in patients with CN-AML [9, 16, 17]. There-
fore, we examined the incidence and interactions of NPM1mut 
and FLT3-ITD+ in such patients and assessed the validity 
of the newly proposed risk-adapted treatment strategies 
based on these mutations.
MATERIALS AND METHODS
1. Patients and treatment protocol
  Diagnostic bone marrow (BM) samples from 121 adult 
patients with CN-AML (age≤60 years) who had received 
at least one cycle of intensive induction chemotherapy were 
analyzed retrospectively for the presence of NPM1mut and 
FLT3-ITD+. To establish CN-AML, 20 or more metaphase 
cells from the samples had to test positive for normal kar-
yotypes [18]. Approval was obtained from the institutional 
review board for this procedure. All patients gave written 
informed consent for both the treatment and the cry-
opreservation of BM.
  All enrolled patients received intensive remission in-
duction therapy consisting of 3 days of idarubicin (IDA) 
at 12 mg/m
2/day and 7 days of cytarabine at 100 mg/m
2/day 
or N
4-behenoyl-1-D-arabinofuranosylcytosine (BH-AC; 300 
mg/m
2/day for patients younger than 40 years, 200 mg/m
2/day 
for patients older than 40 years). If the patients failed to 
achieve complete remission (CR) after the first round of 
induction chemotherapy, they received reinduction chemo-
therapy using the same regimen. Patients achieving CR re-
ceived three courses of high-dose cytarabine chemotherapy 
(HDAC; 3 g/m
2 every 12 h/day on days 1, 3, and 5) for 
consolidation. These patients were allowed to proceed to 
allogeneic (alloSCT) or autologous stem cell transplantation 
(autoSCT) after one or two courses of HDAC consolidation 
therapy.
2. Mutational analysis
  Genomic DNA was extracted from the diagnostic BM sam-
ples, such as cryopreserved mononuclear cells, by using a 
DNA blood minikit (QIAamp; Qiagen, Valencia, CA, USA) 
according to the manufacturer’s protocol.
  For NPM1mut analysis, NPM1 exon-12 was amplified by 
genomic PCR using primers 5'-TCTGAGTATAAATTTTCT 
TGGAGTCA-3' (sense) and 5'-ACCAAGCAAAGGGTGGAG 
TT-3' (antisense). The reaction mixture contained 1.25 pmol Korean J Hematol 2010;45:36-45.
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Table 1. Patient characteristics according to the NPM1mut status.
Parameter NPM1wt NPM1mut Total AML P
No. of patients 56 (46.3) 65 (53.7) 121
Age (yr) 43 (15-60) 47 (16-60) 44 (15-60) 0.65
Sex 0.86
Male 27 (48.2) 30 (46.2) 57 (47.1)
Female 29 (51.8) 35 (53.8) 64 (52.9)
FAB subtype NA
M0 3 (5.4) 2 (3.1) 5 (4.1)
M1 12 (21.4) 12 (18.5) 24 (19.8)
M2 18 (32.1) 20 (30.8) 38 (31.4)
M4 9 (16.1) 9 (13.8) 18 (14.9)
M5 4 (7.1) 10 (15.4) 14 (11.6)
M6 2 (3.6) 4 (6.2) 6 (5.0)
M7 3 (5.4) 0 3 (2.5)
Secondary
leukemia
4 (7.1) 8 (12.3) 12 (9.9)
Unknown 1 (1.8) 0 1 (0.8)
WBC (×10
9/L) 11.8 
(0.5-333.2)
29.7
(1.3-190.4)
25.0
(0.5-333.2)
0.03
Hb (g/dL) 7.2
(3.1-10.6)
8.4
(4.9-12.9)
7.6
(3.1-12.9)
0.23
Platelets (×10
9/L) 46 (19-87) 62 (5-150) 61 (5-150) 0.22
BM blasts (%) 78 (20-99) 80 (20-100) 80 (20-100) 0.50
AlloSCT 24 (42.9) 29 (44.6) 53 (43.8) 0.86
AutoSCT 4 (7.1) 1 (1.5) 5 (4.1) 0.18
FLT3-ITD+ 16 (28.6) 30 (46.2) 46 (38.0) 0.04
The values represent either the number (percentage) or the median
(range).
Abbreviations: NPM1wt, wild-type nucleophosmin gene; NPM1mut,
nucleophosmin gene mutation NA, not applicable; BM, bone 
marrow; alloSCT, allogeneic stem cell transplantation autoSCT; 
autologous stem cell transplantation FLT3-ITD, fms-like tyrosine 
kinase 3 gene-internal tandem duplication.
of each primer, 50 ng of genomic DNA, 250 μM dNTPs, 
and 0.5 U f-taq polymerase (Solgent, Daejeon, Korea) in 
the buffer provided by the manufacturer. Amplification was 
performed in a thermal cycler (PTC 200; MJ Research, Inc., 
Waltham, MA, USA), and the PCR fragments were purified 
(GENEALL PCR Purification Kit; General Biosystem, Seoul, 
Korea). The sequencing reactions were analyzed by using 
a sequencer (ABI 3100) and cycle sequencing kit (BigDye 
Terminator; Applied Biosystems, Foster City, CA, USA).
  For FLT3-ITD+ analysis, wild-type FLT3 exon-11 and 
exon-12 were amplified by genomic PCR using primers 
5'-CAATTTAGGTATGAAAGCC-3' (sense) and 5'-CTTTCA 
GCATTTTGACGGCAACC-3' (antisense). The reaction mix-
ture contained 2.5 mM dNTPs, 2.5 mM MgCl2, 0.5 μM of 
each primer, and 0.5 U f-taq polymerase in a total volume 
of 20 μL. The samples were amplified by initial denaturation 
at 95
oC for 5 min, followed by 35 cycles of 94
oC for 30 
sec, 53
oC for 1 min, and 72
oC for 2 min, and final extension 
at 72
oC for 10 min. The PCR products (10 μL) were resolved 
on 6% polyacrylamide gels, stained with ethidium bromide, 
and photographed under ultraviolet light.
3. Statistical analysis
  The response to initial therapy was evaluated after in-
duction or after salvage chemotherapy. The definition of 
CR followed the recommended criteria [19]. Relapse was 
defined as the reappearance of blasts post-CR in the periph-
eral blood or BM. Relapse-free survival (RFS) endpoints, 
measured from the date of documented CR, included relapse, 
patient death from any cause, and alive in CR at last follow-up 
(censored). The overall survival (OS) endpoints, measured 
from the date of diagnosis, were death from any cause and 
alive at last follow-up (censored) [19]. RFS before trans-
plantation and OS before transplantation were also assessed 
to eliminate confounding bias and were defined as the time 
without relapse, death, or transplantation from the date of 
CR and the time from diagnosis to death or transplantation, 
respectively. 
  For between-group comparisons, Fisher’s exact test (cate-
gorical data) and the Mann-hitney U test (continuous data) 
were used. Categorical data were compared among three 
groups defined by the NPM1 and FLT3-ITD mutation status 
using one-way analysis of variance (ANOVA) and the post 
hoc Tukey’s honestly significant difference (HSD) test. Con-
tinuous variables were compared among the three groups 
by using the Kruskal-Wallis test. RFS and OS were analyzed 
by means of Kaplan-Meier survival curve estimates and log- 
rank tests to compare differences in the distribution of surviv-
al for the three groups. Multivariate analysis using forward 
conditional selection of variables was performed with the 
Cox’s proportional-hazards model to analyze the influence 
of high WBC count (＞50×10
9/μL versus ≤50×10
9/μL), sec-
ondary AML (versus de novo AML), alloSCT, autoSCT, and 
the NPM1 and FLT3-ITD mutation status or the interaction 
of these mutations. A P-value of less than 0.05 was considered 
statistically significant. All statistical computations were per-
formed by using SPSS software version 17.0 (SPSS, Inc., 
Chicago, IL, USA).
RESULTS
1. Patient characteristics
  The median age of the 57 male and 64 female patients 
was 44 years (range, 15-60 years). All patients received in-
tensive remission induction chemotherapy. Fifty-three (43.8%) 
and five (4.1%) of the patients underwent alloSCT and 
autoSCT, respectively. The median follow-up time was 11.8 
months (range, 0.6-86.1 months).
  Among the patients, 65 (53.7%) had NPM1mut at exon-12. 
All patients carrying NPM1mut had the type A mutation. 
Details of the presenting features by the NPM1mut status 
are listed in Table 1. The median peripheral WBC count 
at diagnosis was significantly higher in the NPM1mut group 
than in the NPM1wt group (P=0.03). Furthermore, the NPM1mut 
group showed a higher incidence of FLT3-ITD+ than the 
unmutated group (P=0.04).
  To follow the current NCCN guidelines, we categorized 
the patients into three groups: NPM1mut/FLT3-ITD-, NPM1mut/ Korean J Hematol 2010;45:36-45.
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Table 3. Treatment outcomes according to the NPM1mut status.
Parameter NPM1wt NPM1mut Total AML P
No. of patients 56 (46.3) 65 (53.7) 121
CR1
a) 34 (60.7) 40 (61.5) 74 (61.2) 0.94
CR total
b) 43 (76.8) 50 (76.9) 93 (76.9) 0.99
Resistant 12 (21.4) 14 (21.5) 26 (21.5) 0.99
Early death 1 (1.8) 1 (1.5) 2 (1.7) NA
Relapse before SCT 15 (34.9) 9 (18.0) 24 (25.8) 0.06
Overall relapse 20 (47.6)
c) 18 (36.0) 38 (41.3)
c) 0.26
4-yr RFS before SCT 0 45.4±1.4 24.7±10.3 0.00
4-yr OS before SCT 15.6±12.5 59.8±11.3 41.8±9.0 0.04
5-yr RFS 20.2±15.1 49.1±8.7 39.5±7.8 0.18
5-yr OS 44.2±9.1 52.5±7.7 48.8±5.8 0.29
The values represent either the number (percentage) or the mean 
±SD. 
a)Patients achieved CR after one course of remission induction 
chemotherapy, 
b)Patients achieved CR regardless of induction 
chemotherapy, 
c)One patient was missing due to follow-up loss.
Abbreviations: NPM1wt, wild-type nucleophosmin gene; NPM1mut,
nucleophosmin gene mutation CR, complete remission; NA, not 
applicable; SCT, stem cell transplantation; RFS, relapse-free 
survival; OS, overall survival.
Table 2. Patient characteristics according to the NPM1mut and 
FLT3-ITD+ status.
Parameter
NPM1mut/
FLT3-ITD-
NPM1wt/
FLT3-ITD- NPM1wt/
FLT3-ITD+
P
NPM1mut/
FLT3-ITD+
No. of patients 35 (28.9) 70 (57.9) 16 (13.2)
Age (yr) 50 (23-60) 43 (16-60) 44 (15-54) 0.49
Sex 0.51
Male 19 (54.3) 32 (45.7) 6 (37.5)
Female 16 (45.7) 38 (54.3) 10 (62.5)
FAB subtypes NA
M0 2 (5.7) 3 (4.3) 0
M1 5 (14.3) 15 (21.4) 4 (25.0)
M2 15 (42.9) 20 (28.6) 3 (18.8)
M4 3 (8.6) 9 (12.9) 6 (37.5)
M5 5 (14.3) 8 (11.4) 1 (6.3)
M6 2 (5.7) 4 (5.7) 0
M7 0 2 (2.9) 1 (6.3)
Secondary
leukemia
3 (8.6) 8 (11.4) 1 (6.3)
Unknown 0 1 (1.4) 0
WBC (10
9/L) 29.7
(1.3-178.8)
20.7
(0.5-333.2)
37.9
(6.4-74.9)
0.38
Hb (g/dL) 9.2
(4.9-12.9)
7.5
(3.1-10.8)
8.7
(7.1-9.2)
0.42
Platelets (10
9/L) 66.6 (5-150) 45 (19-116) 68 (25-87) 0.50
BM blasts (%) 74 (20-90) 80 (20-100) 79 (20-98) 0.27
AlloSCT 13 (37.1) 34 (48.6) 6 (37.5) 0.57
AutoSCT 1 (2.9) 3 (4.3) 1 (6.3) 0.82
The values represent either the number (percentage) or the median
(range). 
Abbreviations: NPM1wt, wild-type nucleophosmin gene; NPM1mut,
nucleophosmin gene mutation FLT3-ITD, fms-like tyrosine kinase 
3-internal tandem duplication; NA, not applicable; BM, bone 
marrow; alloSCT, allogeneic stem cell transplantation; autoSCT; 
autologous stem cell transplantation.
FLT3-ITD+ or NPM1wt/FLT3-ITD-, NPM1wt/FLT3-ITD+. Table 
2 shows the baseline characteristics of these groups. There 
was no difference among the groups with regard to age 
and gender. The NPM1wt/FLT3-ITD+ group showed the 
highest initial WBC count; however, there was no statistical 
significance among the groups.
2. Prognostic impact of NPM1
  Of the 121 patients, 93 (76.9%) achieved CR. Among these, 
19 patients failed to achieve CR after the first round of 
induction chemotherapy and therefore received reinduction 
chemotherapy (Table 3). There was no difference in the 
remission rate to induction chemotherapy between the pa-
tients with and those without NPM1mut (76.9% versus 
76.8%, P=0.99). Among the patients who achieved CR, the 
NPM1mut group showed a lower relapse rate before SCT 
(18.0% versus 34.9%, P=0.06) and lower overall relapse rate 
(36.0% versus 47. 6%, P=0.26), although the differences were 
not statistically significant. Before undergoing SCT, the 
NPM1mut group showed a significantly higher rate of 4-year 
RFS (45.4% versus 0%, P=0.00) and OS (59.8% versus 15.6%, 
P=0.04) than the NPM1wt group (Fig. 1A). Overall RFS 
and OS also showed a trend toward better prognosis in the 
NPM1mut group (Fig. 1B). 
  In the subgroup analysis, the overall RFS was significantly 
longer among the patients who underwent alloSCT than 
among the nontransplant patients (P=0.01) in the NPM1wt 
group (Fig. 2A). On the other hand, in the NPM1mut group, 
a trend for longer RFS was observed among the alloSCT 
patients than the nontransplant patients, but the difference 
was not statistically significant (P=0.34; Fig. 2B). Although 
few patients underwent autoSCT (N=5), this procedure did 
not influence the overall relapse rate, RFS, and OS (data 
not shown).
  According to the multivariate analysis for the overall RFS, 
NPM1mut (versus NPM1wt, OR=0.49, 95% CI=0.26-0.92, 
P=0.03), FLT3-ITD- (versus FLT3-ITD+, OR=0.32, 95% CI= 
0.17-0.60, P=0.00), and alloSCT (versus chemotherapy only, 
OR=0.41, 95% CI=0.22-0.77, P=0.01) were independently 
associated with longer overall RFS, after adjusting for high 
WBC counts (≥50×10
9/μL versus ＜50×10
9/μL) and secon-
dary AML (versus de novo AML) (Table 4). In the multi-
variate analysis for the overall OS, NPM1mut failed to be 
an independent prognostic factor, whereas FLT3-ITD- and 
alloSCT were independent, favorable prognostic factors 
(Table 4).
3. Prognostic impact of the interactions between NPM1mut 
and FLT3-ITD+
  In agreement with the previous reports, our study showed 
that the FLT3-ITD+ status was significantly associated with 
NPM1mut in terms of the incidence and clinical outcomes; Korean J Hematol 2010;45:36-45.
40 Yeo-Kyeoung Kim, et al. 
Fig. 2. RFS analysis of the alloSCT patients versus the chemotherapy-alone patients according to the NPM1mut status. (A) Overall RFS in the NPM1wt
group. The overall RFS was significantly longer among the alloSCT patients than among the chemotherapy-alone patients (P=0.01). (B) Overall RFS
in the NPM1mut group. A trend of longer survival was observed among the alloSCT patients than among the chemotherapy-alone patients, but the 
difference was not statistically significant (P=0.34). Abbreviations: NPM1mut, nucleophosmin gene mutation; NPM1wt, wild-type nucleophosmin
gene; RFS, relapse-free survival; alloSCT, allogeneic stem cell transplantation.
Fig. 1. Kaplan-Meier analysis of CN-AML according to the NPM1mut status. (A) RFS and OS before SCT. (B) Overall RFS and OS. Abbreviations: CN,
cytogenetically normal; NPM1mut, nucleophosmin gene mutation; NPM1wt, wild-type nucleophosmin gene; RFS, relapse-free survival; OS, overall
survival; SCT, stem cell transplantation.
hence, we assessed the prognostic impact of the three groups 
according to the NPM1mut and FLT3-ITD+ status (Table 
5). The highest remission rate was found in the NPM1mut/ 
FLT3-ITD- group (80.0%); however, the differences among 
the groups were not statistically significant. The relapse rate 
before SCT was higher in the NPM1wt/FLT3-ITD+ group Korean J Hematol 2010;45:36-45.
NPM1 and FLT3-ITD mutations in adult CN-AML 41
Table 4. Multivariable analysis for outcome according to the 
NPM1mut and FLT3-ITD+ status.
Variable
RFS OS
OR
(95% CI)
P
OR
(95% CI)
P
NPM1wt
NPM1mut 0.49
(0.26-0.92)
0.03 NA NA
FLT3-ITD+
FLT3-ITD− 0.32
(0.17-0.60)
0.00 0.42
(0.23-0.77)
0.01
Interaction of NPM1 
and FLT3-ITD
NPM1mut/FLT3-ITD−
NPM1wt/FLT3-ITD− 0.30
(0.14-0.64)
0.00 0.32
(0.15-0.69)
0.00
NPM1mut/FLT3-ITD−
NPM1wt/FLT3-ITD+ 0.16
(0.06-0.40)
0.00 0.20
(0.08-0.50)
0.00
AlloSCT
No
Yes 0.43
(0.23-0.81)
0.01 0.35
(0.18-0.66)
0.00
Abbreviations: NPM1wt, wild-type nucleophosmin gene; NPM1mut,
nucleophosmin gene mutation FLT3-ITD, fms-like tyrosine kinase 3
gene-internal tandem duplication; RFS, relapse-free survival; OS, 
overall survival; OR, odds ratio; 95% CI, 95% confidence interval;
NA, not applicable; alloSCT, allogeneic stem cell transplantation.
Table 5. Treatment outcomes according to the NPM1mut and 
FLT3-ITD+ status.
Parameter
NPM1mut/
FLT3-ITD-
NPM1wt/
FLT3-ITD- NPM1wt/
FLT3-ITD+
P
NPM1mut/
FLT3-ITD+
No. of patients 35 (28.9) 70 (57.9) 16 (13.2)
CR1
a) 21 (60.0) 43 (61.4) 10 (62.5) 1.00
CR total
b) 28 (80.0) 53 (75.7) 12 (75.0) 0.78
Resistant 6 (17.1) 16 (22.9) 4 (25.0) 0.78
Early death 1 (2.9) 1 (1.4) 0 0.75
Relapse 
before SCT
6 (21.4) 13 (24.5) 5 (41.7) 0.40
Overall relapse 8 (28.6) 20 (38.5)
c) 10 (83.3) 0.00
5-yr RFS 
before SCT
52.4±15.7 11.9±10.7 NA 0.00
5-yr OS 
before SCT
61.4±12.0 34.8±14.8 0 0.02
5-yr RFS 60.5±10.8 35.4±12.3 0 0.00
5-yr OS 62.6±9.1 47.1±8.7 NA 0.00
The values represent either the number (percentage) or the mean 
±SD. 
a)Patients achieved CR after one course of remission induction 
chemotherapy, 
b)Patients achieved CR regardless of induction 
chemotherapy, 
c)One patient was missing due to follow-up loss.
Abbreviations: NPM1wt, wild-type nucleophosmin gene; NPM1mut,
nucleophosmin gene mutation FLT3-ITD, fms-like tyrosine kinase 3
gene-internal tandem duplication; CR, complete remission; SCT, 
stem cell transplantation; RFS, relapse-free survival; NA, not 
applicable; OS, overall survival. 
(41.7%) than in the NPM1mut/FLT3-ITD- group (21.4%) 
and the other groups (NPM1wt/FLT3-ITD- or NPM1mut/ 
FLT3-ITD+, 24.5%). Furthermore, the overall relapse rate 
was significantly higher in the isolated FLT3-ITD+ group 
(83.3%) than in the isolated NPM1mut (28.6%) and the 
other groups (38.5%). The post hoc test also revealed that 
the NPM1wt/FLT3-ITD+ group had a significantly higher 
overall relapse rate than the NPM1mut/FLT3-ITD- (P= 0.00) 
or the other groups (P=0.01). The highest 5-year RFS and 
OS were observed in the isolated NPM1mut group regardless 
of SCT, followed by the NPM1wt/FLT3-ITD- or 
NPM1mut/FLT3-ITD+ group and the isolated FLT3-ITD+ 
groups (Fig. 3).
  We also conducted further analysis for the overall RFS 
following alloSCT compared with chemotherapy alone as 
a consolidation therapy. In the isolated NPM1mut group, 
13 patients (37.1%) underwent alloSCT whereas 20 (57.1%) 
received chemotherapy alone. The CR rate in the alloSCT 
group and chemotherapy-alone group was 69.2% and 55%, 
respectively (P=0.49). Twelve patients (92.3%) achieved CR 
at transplantation. One (7.7%) was refractory to all three 
courses of previous remission induction chemotherapy; in 
spite of alloSCT, the patient could not achieve CR and died 
of pneumonia 3 months after SCT. Peripheral blood stem 
cells collected from sibling donors (s-PBSCs, N=11), unrelated 
bone marrow stem cells (u-BMs, N=1), and unrelated PBSCs 
(u-PBSCs, N=1) were used as the hematopoietic stem cell 
sources. Conditioning regimens consisted of Flu/Bu (fludar-
abine at 30 mg/m
2/day for 6 days and busulfan at 3.2 mg/ 
kg/day for 4 days, N=9), TBI/Cy (total body irradiation at 
13.2 Gy in 4 days with cyclophosphamide at 60 mg/day 
in 2 days, N=3), and Bu/Cy (busufan with cyclophosphamide, 
N=1). The median number of infused CD34+ cells was 5.3× 
10
6/kg (range=0.7-13.2). As depicted in Fig. 4, alloSCT sig-
nificantly influenced the longer (5-year) RFS in the isolated 
NPM1mut group (alloSCT versus chemotherapy alone, 87.5%. 
versus 42.7%, P=0.03; Fig. 4A). In addition, we conducted 
a subgroup analysis of 21 patients who achieved CR after 
one cycle of induction chemotherapy (9 in alloSCT group, 
11 in chemotherapy-alone group, and 1 in autoSCT group). 
The alloSCT group showed a significantly lower rate of over-
all relapse (0% versus 36.4%, P=0.04) and higher 5-year 
overall RFS (100% versus 52.5%, P=0.04) than the chemo-
therapy-alone group. Although statistically insignificant, the 
patients with NPM1wt/FLT3- ITD- or NPM1mut/FLT3- 
ITD+ who underwent alloSCT (5-year RFS=63.6%) showed 
better overall RFS than the chemotherapy-alone patients 
(15.1%, P=0.12; Fig. 4B). Among the patients with isolated 
FLT3-ITD+, the overall RFS in the alloSCT group (N=6) 
was not significantly different from that in the chemo-
therapy-alone group (N=9; Fig. 4C). s-PBSCs (N=4), u-PBSCs 
(N=1), and u-BMs (N=1) were used as the stem cell sources 
and all patients underwent alloSCT at CR status. The con-Korean J Hematol 2010;45:36-45.
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Fig. 3. Kaplan-Meier analysis of CN-AML for RFS and OS according to the combined NPM1mut and FLT3-ITD+ status. (A) RFS and OS before 
transplantation. (B) Overall RFS and OS. Abbreviations: CN, cytogenetically normal; NPM1mut, nucleophosmin gene mutation; NPM1wt, wild-type
nucleophosmin gene; FLT3-ITD, fms-like tyrosine kinase 3 gene-internal tandem duplication; RFS, relapse-free survival; OS, overall survival.
ditioning regimens consisted of Flu/Bu (N=4) and TBI/Cy 
(N=2). The median number of infused CD34+ cells was 4.5× 
10
6/kg (range=2.6-7.8). Four patients in the alloSCT group 
died of leukemic relapse, and there was no significant correla-
tion between the relapse rate or RFS and the conditioning 
regimen or the stem cell source.
  The multivariate analysis for the overall RFS and OS also 
identified the combination of NPM1 and FLT3-ITD muta-
tions and alloSCT as independent prognostic factors after 
adjusting for high WBC count (≥50×10
9/μL versus ＜50×10
9/μL) 
and secondary AML (versus de novo A M L )  ( T a b l e  4 ) .
DISCUSSION
  We evaluated the prevalence and prognostic impact of 
NPM1mut and FLT3-ITD+ and their interactions in adult 
patients with CN-AML. The incidence of NPM1mut and 
FLT3-ITD+ was 53.7% and 38%, respectively, suggesting 
that they are frequent molecular events in such patients. 
The incidence of FLT3-ITD+ was higher in the NPM1mut 
group than in the NPM1wt group. Previous studies have 
reported a considerable correlation between these two muta-
tions, suggesting that they are secondary events from a pri-
mary process that predisposes myeloid stem and progenitor 
cell errors in DNA replication [10, 11]. Others have demon-
strated that the NPM1mut/allele ratio is higher than the 
FLT3-ITD+/wild-type ratio, suggesting that NPM1mut oc-
curs prior to FLT3-ITD+ in cases with both mutations [9]. 
  According to previous studies, patients with CN-AML car-
rying NPM1mut show a higher rate of CR, suggesting that 
these patients are more sensitive to chemotherapeutic agents 
[11, 12, 20]. These studies assumed that NPMc+ may interact 
with and sequester nuclear factor kappaB (NF-κB), con-
tributing to the maintenance and survival of malignant clones 
and an impaired response to chemotherapy in the cytoplasm, 
leading to its inactivation and reduced DNA binding [20]. 
However, in other studies, patients younger than 60 years 
and pediatric patients did not show a significantly different 
CR rate between NPM1wt and NPM1mut [9, 16, 17]. In 
the present study, there were no significant differences in 
the CR rate between NPM1mut and NPM1wt. Although 
the patients with NPM1mut/FLT3-ITD- CN-AML showed 
a slightly higher CR rate than the other groups, the differ-Korean J Hematol 2010;45:36-45.
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ences were not statistically significant.
  On the other hand, we demonstrated that the NPM1mut 
group had better RFS and OS before SCT than the NPM1wt 
group, although the differences were not statistically signi-
ficant. A recent study has demonstrated that non-A type 
NPM1mut individuals show different clinical outcomes com-
pared with those having the type A mutation [21]. In the 
present study, however, all the NPM1mut individuals pos-
sessed type A mutations. In the multivariate analysis to eval-
uate other factors influencing the overall RFS and OS, 
FLT3-ITD+ and alloSCT treatment were identified as in-
dependent prognostic factors (besides the NPM1mut status). 
  For CN-AML, the proper risk-stratified postremission 
therapy has not yet been determined. Previous studies on 
young adult patients with CN-AML have reported a 4-year 
DFS of 48.5% with alloSCT [22] and 5-year DFS of 28-41% 
with repeated courses of HDAC consolidation [23, 24]. 
Hence, transplant-based options generally afford a lesser risk 
of relapse and higher DFS as consolidation for the patients. 
However, this benefit is accompanied by a treatment-related 
mortality of 15-25% [25]. To balance the treatment-related 
toxicity and risk of relapse, it is crucial to define distinct 
clinical and molecular subtypes that influence the prognosis 
of CN-AML.
  It was previously reported that event-free survival (EFS) 
and DFS are better in patients with NPMc+/FLT3-ITD- than 
in those with other CN-AML subtypes [9, 12]. Some studies 
have also shown that the 5-year EFS and OS of patients 
with NPMc+/FLT3-ITD- are comparable to those with favor-
able cytogenetics [16, 17], suggesting that this group of pa-
tients could be considered a favorable group. Others have 
reported that the RFS and OS are significantly better in 
the NPMc+/FLT3-ITD- group than the other groups, and 
suggested that alloSCT has no effect on the RFS and OS 
in this subset of CN-AML [11]. Therefore, the NCCN guide-
lines for AML consider patients with isolated NPM1mut 
as a favorable-risk group and recommended multiple cycles 
of HDAC as a reasonable option. Further, patients carrying 
isolated FLT3-ITD+ constitute a poor-risk cytogenetic group 
that should be considered for clinical trials or early alloSCT 
[15]. However, other studies have reported variable results 
about the clinical outcomes according to the presence of 
these mutations; the FLT3-ITD+ status was prognostically 
significant only in the patients with NPM1wt [18, 19].
  In our three-group analysis, the isolated NPM1mut group 
had a significantly better overall relapse rate and the highest 
rate of 5-year RFS and OS, regardless of SCT. Further, in 
this group, alloSCT significantly increased the 5-year RFS 
rate. For patients carrying favorable cytogenetics such as 
t(8;21) or inv (16), multiple courses of HDAC are known 
Fig. 4. RFS analysis of the alloSCT patients versus the chemotherapy- 
alone patients according to the combined NPM1mut and FLT3-ITD+ 
status. (A) NPM1mut/FLT3-ITD- (isolated NPM1mut) group. (B) NPM1mut/ 
FLT3-ITD+ or NPM1wt/FLT3-ITD- group. (C) NPM1wt/FLT3-ITD+ (iso-
lated FLT3-ITD+) group. In the NPM1mut/FLT3-ITD- group, the alloSCT 
patients had significantly longer RFS than the chemotherapy- alone 
patients (A). The NPM1mut/FLT3-ITD+ or NPM1wt/FLT3-ITD- group 
also displayed a longer trend of RFS with alloSCT (B). In contrast, the 
patients with NPM1wt/FLT3-ITD+ showed significantly shorter RFS 
and alloSCT did not improve the outcome of this subset (C). Abbrevi-
ations: NPM1mut, nucleophosmin gene mutation; NPM1wt, wild-type 
nucleophosmin gene; FLT3-ITD, fms-like tyrosine kinase 3 gene-internal 
tandem duplication; RFS, relapse-free survival; alloSCT, allogeneic 
stem cell transplantation.Korean J Hematol 2010;45:36-45.
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to lead to 50-60% of 4-year DFS [24, 26]. In the present 
study, the 5-year RFS was 42.7% for the patients treated 
only with HDAC consolidation in the isolated NPM1mut 
group, lower than that among patients with favorable cyto-
genetics. The patients who underwent alloSCT, however, 
showed a significantly better 5-year RFS rate (87.5%) than 
the chemotherapy-alone patients in the isolated NPM1mut 
group. Therefore, the role of alloSCT in patients with NPM1mut/ 
FLT3-ITD- CN-AML should be reconsidered.
  In contrast, the isolated FLT3-ITD+ group showed poor 
clinical outcomes in terms of the overall relapse rate, RFS, 
and OS, regardless of SCT. All patients relapsed or died 
within 2 years after diagnosis, and alloSCT did not change 
their RFS.
  In the NPM1wt/FLT3-ITD- or NPM1mut/FLT3-ITD+ 
group, the 5-year RFS increased remarkably (but not sig-
nificantly) with alloSCT compared with the chemotherapy- 
alone patients, who showed a remarkably lower rate of 5-year 
RFS (15.1%) than the patients who underwent alloSCT 
(63.6%). Therefore, alloSCT seems to be a reasonable option 
for this subset of patients.
  In summary, adult patients (≤60 years) with CN-AML 
carrying isolated NPM1mut and FLT3-ITD+ show different 
clinical outcomes than those bearing both mutated or 
wild-type NPM1 and FLT3-ITD. Furthermore, isolated NPM1mut 
is associated with favorable clinical outcomes in patients 
with CN-AML; however, the efficacy of alloSCT as a treat-
ment option for this group of patients remains to be 
determined.
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